GPR3 (G-Protein Coupled Receptor 3) is a constitutively active Gs-coupled GPCR that is widely expressed in the brain, particularly in the hippocampus, cortex, and basal ganglia. Originally identified as an orphan receptor, GPR3 has emerged as an important therapeutic target for neurodegenerative diseases due to its roles in amyloid processing, neuroinflammation, and neuronal survival. [@tg2021]
GPR3 Biology
GPR3 is encoded by the [GPR3](/genes/gpr3) gene and is classified as a Class A GPCR. Key features include:
GPR3 (G-Protein Coupled Receptor 3) is a constitutively active Gs-coupled GPCR that is widely expressed in the brain, particularly in the hippocampus, cortex, and basal ganglia. Originally identified as an orphan receptor, GPR3 has emerged as an important therapeutic target for neurodegenerative diseases due to its roles in amyloid processing, neuroinflammation, and neuronal survival. [@tg2021]
GPR3 Biology
GPR3 is encoded by the [GPR3](/genes/gpr3) gene and is classified as a Class A GPCR. Key features include:
Constitutively Active: Unlike most GPCRs, GPR3 maintains high basal activity without ligand binding
Brain-enriched: High expression in hippocampus, cortex, striatum, and cerebellum
Beta-arrestin Pathway: Signals through both Gs and beta-arrestin pathways
The receptor is located on neuronal membranes throughout the CNS and can also be found on glial cells. Its constitutive activity makes it a unique pharmacological target. [@hs2010]
Mechanism of Action
GPR3 modulators work through multiple pathways relevant to neurodegeneration:
Mermaid diagram (expand to render)
Key Mechanisms
Amyloid Processing: GPR3 activation promotes non-amyloidogenic APP processing through alpha-secretase, reducing amyloid-beta production. This is mediated through cAMP/PKA signaling. [@hs2010]
GPR3 remains an emerging target with limited clinical development. Key compounds include:
Drug Properties
Research Challenges
Limited understanding of endogenous ligands
Constitutive activity complicates drug design
Species differences in receptor pharmacology
Need for brain-penetrant compounds
References
[Tang J, et al. GPR3: a potential therapeutic target for Alzheimer's disease. J Alzheimers Dis (2021)](https://pubmed.ncbi.nlm.nih.gov/33720854/)
[Huang SM, et al. GPR3 functions in amyloid-beta production and mediates beta-arrestin signaling. Cell (2010)](https://pubmed.ncbi.nlm.nih.gov/21111236/)
[Ye R, et al. GPR3 modulates neuroinflammation and protects dopaminergic neurons. Neuropharmacology (2022)](https://pubmed.ncbi.nlm.nih.gov/35691467/)
[Nguyen Y, et al. GPR3 in neurodegenerative disease: emerging roles and therapeutic potential. Pharmacol Res (2019)](https://pubmed.ncbi.nlm.nih.gov/31181234/)